Nautilus Biotechnology (NASDAQ:NAUT) Stock Price Down 3.8% – What’s Next?

Nautilus Biotechnology, Inc. (NASDAQ:NAUT)’s stock price was down 3.8% during trading on Thursday . The company traded as low as $2.23 and last traded at $2.27. Approximately 556,419 shares were traded during mid-day trading, an increase of 43% from the average session volume of 390,083 shares. The stock had previously closed at $2.36.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on NAUT shares. Weiss Ratings restated a “sell (d-)” rating on shares of Nautilus Biotechnology in a research note on Tuesday, April 21st. Guggenheim lifted their target price on shares of Nautilus Biotechnology from $2.50 to $4.00 and gave the stock a “buy” rating in a report on Friday, February 27th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $4.00.

Nautilus Biotechnology Stock Performance

The stock has a market cap of $288.47 million, a P/E ratio of -4.93 and a beta of 0.75. The firm has a 50 day moving average of $2.58 and a two-hundred day moving average of $2.48.

Nautilus Biotechnology (NASDAQ:NAUT) last issued its quarterly earnings results on Tuesday, April 28th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.02.

Insider Transactions at Nautilus Biotechnology

In related news, major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of the business’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $2.35, for a total transaction of $11,750,000.00. Following the transaction, the insider owned 971,885 shares of the company’s stock, valued at approximately $2,283,929.75. The trade was a 83.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 41.10% of the company’s stock.

Institutional Trading of Nautilus Biotechnology

Hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC increased its holdings in shares of Nautilus Biotechnology by 19.6% during the 4th quarter. Virtu Financial LLC now owns 23,532 shares of the company’s stock worth $46,000 after purchasing an additional 3,849 shares during the period. Bridgeway Capital Management LLC lifted its stake in shares of Nautilus Biotechnology by 4.0% in the fourth quarter. Bridgeway Capital Management LLC now owns 130,000 shares of the company’s stock valued at $254,000 after buying an additional 5,000 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Nautilus Biotechnology by 2.2% in the first quarter. Renaissance Technologies LLC now owns 265,700 shares of the company’s stock valued at $1,031,000 after buying an additional 5,800 shares during the period. Geode Capital Management LLC grew its position in Nautilus Biotechnology by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 560,909 shares of the company’s stock worth $1,094,000 after buying an additional 7,307 shares in the last quarter. Finally, CTC Alternative Strategies Ltd. acquired a new stake in Nautilus Biotechnology during the first quarter worth about $48,000. 50.71% of the stock is owned by institutional investors.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.